thalidomide has been researched along with Hemangioendothelioma in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hemangioendothelioma: A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, a well-known immunomodulatory compound, has an anti-angiogenic activity, which may be utilized for the treatment of angiogenesis-related diseases such as hemangioendothelioma." | 7.91 | Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma. ( Guo, L; Liu, H; Liu, L; Ren, L; Song, N; Wan, Z; Xu, B, 2019) |
| "Thalidomide, a well-known immunomodulatory compound, has an anti-angiogenic activity, which may be utilized for the treatment of angiogenesis-related diseases such as hemangioendothelioma." | 3.91 | Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma. ( Guo, L; Liu, H; Liu, L; Ren, L; Song, N; Wan, Z; Xu, B, 2019) |
| " Subsequent investigations resulted in the diagnosis of type I cryoglobulinemia; the lesions resolved completely following treatment of the underlying disorder with lenalidomide." | 3.79 | Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner. ( Boyapati, A; Khan, S; Mar, A; Sheridan, A, 2013) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor of childhood that is locally aggressive but has little metastatic potential and by itself is not known to be lethal." | 1.35 | Kaposiform hemangioendothelioma in multiple spinal levels without skin changes. ( Bradeen, HA; Kalof, AN; Lisle, JW, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, L | 1 |
| Wan, Z | 1 |
| Xu, B | 1 |
| Ren, L | 1 |
| Liu, H | 1 |
| Song, N | 1 |
| Liu, L | 1 |
| Boyapati, A | 1 |
| Khan, S | 1 |
| Mar, A | 1 |
| Sheridan, A | 1 |
| Lisle, JW | 1 |
| Bradeen, HA | 1 |
| Kalof, AN | 1 |
3 other studies available for thalidomide and Hemangioendothelioma
| Article | Year |
|---|---|
Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Movement; Hemangioendothelioma; Humans; Mice; Ribonu | 2019 |
Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner.
Topics: Aged; Angiogenesis Inhibitors; Cryoglobulinemia; Hemangioendothelioma; Humans; Lenalidomide; Male; R | 2013 |
Kaposiform hemangioendothelioma in multiple spinal levels without skin changes.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Celecoxib; Chil | 2009 |